These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18981785)

  • 1. Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
    Fleischbein E; O'Brien J; Martelino R; Fenstersheib M
    AIDS; 2008 Nov; 22(17):2404-5. PubMed ID: 18981785
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 3. [Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():24-5. PubMed ID: 25026852
    [No Abstract]   [Full Text] [Related]  

  • 4. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 5. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 6. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 7. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
    Med Lett Drugs Ther; 2003 Nov; 45(1169):90-2. PubMed ID: 14603099
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV therapeutics, continued: another HIV protease inhibitor approved.
    Laurence J
    AIDS Read; 2003 Aug; 13(8):355-6. PubMed ID: 14524318
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
    Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
    Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 14. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rash in an HIV-positive patient.
    Herzmann C; Kinloch S; Johnson M
    HIV Med; 2005 Nov; 6(6):379. PubMed ID: 16268818
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug interactions. Brecanavir--a new protease inhibitor.
    TreatmentUpdate; 2006; 18(3):6-7. PubMed ID: 17209240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.